IDEAYA Biosciences (IDYA) Research & Development (2018 - 2026)
IDEAYA Biosciences (IDYA) posted Research & Development of $95.7 million for Q1 2026, up 10.54% sequentially from $86.6 million in Q4 2025, and up 35.04% YoY from $70.9 million in Q1 2025.
IDEAYA Biosciences (IDYA) Research & Development (2018 - 2026) Analysis & Trends
IDEAYA Biosciences has reported Research & Development for 9 years, with the latest figure at $95.7 million in Q1 2026.
- Quarterly Research & Development rose 35.04% year-over-year to $95.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $290.0 million (up 82.02% YoY) and the FY2025 annual result came in at $314.7 million, up 277.24% from the prior year.
- Research & Development rose to $95.7 million in Q1 2026 per IDYA's latest filing, from $86.6 million in the prior quarter.
- Over five years, Research & Development peaked at $95.7 million in Q1 2026 and troughed at -$45.1 million in Q4 2023.
- A 5-year average of $33.8 million and a median of $29.2 million in 2023 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2025: Research & Development tumbled 271.4% in 2022, then soared 633.77% in 2025.
- Over 5 years, Research & Development stood at -$27.6 million in 2022, then tumbled by 63.32% to -$45.1 million in 2023, then surged by 126.17% to $11.8 million in 2024, then jumped by 633.77% to $86.6 million in 2025, then grew by 10.54% to $95.7 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $95.7 million, $86.6 million, and $33.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | IDEAYA Biosciences | 3.50 Bn | 2.67 Bn | - | 108.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 108.69 Mn |
| Mar 31, 2026 | 95.73 Mn |
| Dec 31, 2025 | 86.60 Mn |
| Sep 30, 2025 | 33.43 Mn |
| Jun 30, 2025 | 74.23 Mn |
| Mar 31, 2025 | 70.89 Mn |
| Dec 31, 2024 | 11.80 Mn |
| Sep 30, 2024 | 22.09 Mn |
| Jun 30, 2024 | 54.53 Mn |
| Mar 31, 2024 | 42.81 Mn |
| Dec 31, 2023 | -45.10 Mn |
| Sep 30, 2023 | 33.70 Mn |
| Jun 30, 2023 | 29.18 Mn |
| Mar 31, 2023 | 27.86 Mn |
| Dec 31, 2022 | -27.61 Mn |
| Sep 30, 2022 | 22.37 Mn |
| Jun 30, 2022 | 22.80 Mn |
| Mar 31, 2022 | 19.66 Mn |
| Dec 31, 2021 | 16.11 Mn |
| Sep 30, 2021 | 15.50 Mn |